COVID-19 in patients with hematologic malignancy

P Langerbeins, M Hallek - Blood, The Journal of the American …, 2022 - ashpublications.org
The coronavirus infectious disease (COVID-19) shows a remarkable symptomatic
heterogeneity. Several risk factors including advanced age, previous illnesses, and a …

The importance of measuring SARS-CoV-2-specific T-cell responses in an ongoing pandemic

L Petrone, A Sette, RD de Vries, D Goletti - Pathogens, 2023 - mdpi.com
Neutralizing antibodies are considered a correlate of protection against SARS-CoV-2
infection and severe COVID-19, although they are not the only contributing factor to …

The WSES/SICG/ACOI/SICUT/AcEMC/SIFIPAC guidelines for diagnosis and treatment of acute left colonic diverticulitis in the elderly

P Fugazzola, M Ceresoli, F Coccolini… - World Journal of …, 2022 - Springer
Acute left colonic diverticulitis (ALCD) in the elderly presents with unique epidemiological
features when compared with younger patients. The clinical presentation is more nuanced in …

Immunogenicity and risks associated with impaired immune responses following SARS-CoV-2 vaccination and booster in hematologic malignancy patients: an …

N Uaprasert, P Pitakkitnukun… - Blood Cancer …, 2022 - nature.com
Patients with hematologic malignancies (HM) have demonstrated impaired immune
responses following SARS-CoV-2 vaccination. Factors associated with poor immunogenicity …

[HTML][HTML] Emergence of Delta and Omicron variants carrying resistance-associated mutations in immunocompromised patients undergoing sotrovimab treatment with …

C Andrés, A González-Sánchez, M Jiménez… - Clinical Microbiology …, 2023 - Elsevier
Objectives To monitor the early emergence of genetic mutations related to reduced
susceptibility to monoclonal anti-body (mAb)-based treatment in immunocompromised …

Robust SARS-CoV-2 T cell responses with common TCRαβ motifs toward COVID-19 vaccines in patients with hematological malignancy impacting B cells

THO Nguyen, LC Rowntree, LF Allen, BY Chua… - Cell Reports …, 2023 - cell.com
Immunocompromised hematology patients are vulnerable to severe COVID-19 and respond
poorly to vaccination. Relative deficits in immunity are, however, unclear, especially after 3 …

SARS-CoV-2 in immunocompromised individuals

S DeWolf, JC Laracy, MA Perales, M Kamboj… - Immunity, 2022 - cell.com
Immunocompromised individuals and particularly those with hematologic malignancies are
at increased risk for SARS-CoV-2-associated morbidity and mortality due to immunologic …

SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease

E Barnes, CS Goodyear, M Willicombe, C Gaskell… - Nature medicine, 2023 - nature.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune responses and
infection outcomes were evaluated in 2,686 patients with varying immune-suppressive …

[HTML][HTML] Immunogenicity of SARS-CoV-2 vaccines in patients with cancer

H Kakkassery, E Carpenter, PEM Patten… - Trends in Molecular …, 2022 - cell.com
Transmission of the SARS-CoV-2 virus and its corresponding disease (COVID-19) has been
shown to impose a higher burden on cancer patients than on the general population …

Adult patients with cancer have impaired humoral responses to complete and booster COVID-19 vaccination, especially those with hematologic cancer on active …

E Liatsou, I Ntanasis-Stathopoulos, S Lykos… - Cancers, 2023 - mdpi.com
Simple Summary Taking into consideration the high risk of patients with cancer for severe
COVID-19 infection, prioritization has been given to primary prevention with both primary …